Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Blood alkaline phosphatase, Blood alkaline phosphatase increased, Condition aggravated, Gamma-glutamyltransferase, Gamma-glutamyltransferase increased
Clinical narrative: highly elevated (440) GGT / GGT in Nov21 elevated to 351 and now 440 Feb 2022; highly elevated alkaline phosphatase/now 222 as of Feb2022; COVID induced liver injury; Condition aggravated; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 58 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administration date 15Nov2021 (Lot number: FG3527) at the age of 58 years as dose 3 (booster), single for covid-19 immunisation in the pharmacy. Relevant medical history included: "PLD polycystic liver" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EW0162), administration date: 13Apr2021, when the patient was 57 years old, for COVID-19 immunization, reaction(s): "highly elevated alkaline phosphatase", "highly elevated GGT", "COVID induced liver injury"; Bnt162b2 (Dose Number: 2, Batch/Lot No: EW0716), administration date: 04May2021, when the patient was 57 years old, for COVID-19 immunization, reaction(s): "highly elevated alkaline phosphatase", "highly elevated GGT", "COVID induced liver injury". The patient did not receive any other vaccine in four weeks. The patient did not have covid prior to vaccination and was not tested post vaccination. The following information was reported: GAMMA-GLUTAMYLTRANSFERASE INCREASED (non-serious) with onset Feb2022, outcome "not recovered", described as "highly elevated (440) GGT / GGT in Nov21 elevated to 351 and now 440 Feb 2022"; BLOOD ALKALINE PHOSPHATASE INCREASED (non-serious) with onset Feb2022, outcome "not recovered", described as "highly elevated alkaline phosphatase/now 222 as of Feb2022"; LIVER INJURY (non-serious) with onset Feb2022, outcome "not recovered", described as "COVID induced liver injury"; CONDITION AGGRAVATED (non-serious) with onset Feb2022, outcome "not recovered", described as "Condition aggravated". The events "highly elevated alkaline phosphatase/now 222 as of feb2022", "covid induced liver injury" and "condition aggravated" were evaluated at the physician office visit. Highly elevated alkaline phosphatase and highly elevated (440) GGT showing COVID induced liver injury. Pre-existing condition PLD polycystic liver disease, but no abnormality in liver function tests etc. Starting in 01Jun2021 (also reported as Jul2021), AP suddenly elevated and continued to elevate progressing from 71 pre-vaccine to 89 after first shot to 158 and now 222 as of Feb2022. GGT in Nov 21 elevated to 351 and now 440 Feb2022. The patient underwent the following laboratory tests and procedures: blood alkaline phosphatase: (unspecified date) highly elevated; (unspecified date) 158; (unspecified date) 71; (01Jun2021) 89; (Feb2022) 222; gamma-glutamyltransferase: (unspecified date) highly elevated; (Nov2021) 351; (Feb2022) 440; liver function test: (unspecified date) no abnormality. It was unknown if therapeutic measures were taken as a result of gamma-glutamyltransferase increased, blood alkaline phosphatase increased, liver injury, condition aggravated.   No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : PFIZER INC-202200195128 same reporter, patient and product; different dose; similar events